Table 2.

Serum sIFNAR2 levels in MS patients.

Cohort 1/Cohort 2	Basal	6 Months	12 Months
N	59/35	59/35	59/35
25% Percentile	19,59/40,44	25,61/45,94	20,41/53,3
Median	33,43/46,01	50,6/60,04	38,97/59,97
75% Percentile	59,16/59,44	70,16/68,44	65/72,15